Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Hims & Hers is now projecting that it hit 2025 targets of $1.2 billion of revenue and $100 million of EBITDA one year early, CEO Andrew Dudum told investors during its Q4 and full-year 2023 ...

HIMS differentiates itself with AI-based individualization of treatments, as opposed to Teladoc (TDOC) with AI-based triaging and GoodRx (GDRX) with drug price optimization.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.